TheraRadar
← Back
Data updated: Jun 28, 2026

ALRA

Generics

ALRA is a generic drug manufacturer focused on Cardiovascular, Neurology, Ophthalmology.

1971
Since
17
Drugs
-
Trials
0
New Drugs (2yr)

ALRA's Key Drugs

ALRA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ALRA's Recent FDA Approvals

New NDA/BLA approvals for ALRA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ALRA's Therapeutic Areas

ALRA's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 40%
2 drugs
Neurology 20%
1 drugs
Ophthalmology 20%
1 drugs
Gastroenterology 20%
1 drugs

ALRA's Top Competitors

ALRA's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Novartis, and VALIDUS PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ALRA Pipeline Snapshot

Active clinical trials for ALRA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling